A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Solriamfetol (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
- 12 Mar 2018 Planned End Date changed from 1 Feb 2017 to 1 Oct 2019.
- 12 Mar 2018 Planned primary completion date changed from 1 Oct 2016 to 1 Jun 2019.
- 28 Jun 2016 New trial record